Acute Graft Versus Host Disease - 162 Studies Found

Completed : A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease
: Graft vs Host Disease
: 2016-10-03
: Biological: Mesenchymoangioblast-derived mesenchymal stem cells The active agent in CYP-001 is allogenei
Completed : Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.
: Chronic Graft-Versus-Host Disease
: 2013-09-30
: Genetic: Allogenic Mesenchymal Stem Cell Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized b
Completed : Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
: Graft vs Host Disease
: 2002-03-14
: Drug: Visilizumab
Completed : Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
:
  • Graft Versus Host Disease
  • Recurrent Adult Acute Lymphoblastic Leukemia

: 2009-06-25
:
  • Drug: prednisone immunosuppres
Completed : Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
: Graft-Versus-Host Disease
: 2015-03-04
: Biological: MSC MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogenei
Recruiting : Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation
: Graft Versus Host Disease
: 2012-05-09
: Drug: Cannabidiol Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing
Not yet recruiting : Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
:
  • Childhood Malignant Neoplasm
  • Hematopoietic Cell Transplantation Recipient

: 2017-02-15
:
  • Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting : Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
:
  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation

: 2016-02-02
: Drug: Sitagliptin 600 mg ever 12 hours by mouth will be given starting the day before transplant through
Active, not recruiting : Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
: Graft vs. Host Disease
: 2012-10-22
:
  • Drug: Ustekinumab One subcutan
Suspended : Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
: Graft Versus Host Disease
: 2015-08-14
:
  • Biological: donor regulatory T lymphocytes

<<< Previous | Next >>>